THERAPEUTIC AREAS OF FOCUS

We are advancing novel science and accelerating potential breakthrough therapies with the goal of delivering transformative medicines and vaccines, and possibly even cures, to patients in need. We focus our efforts in areas where we believe we are best positioned to utilize our expertise and bring unique, needed therapies to patients. More and more, our scientists are reaching into a dynamic R&D ecosystem to find the right partners to improve and accelerate our efforts. This focus and effort are helping to drive our long-term growth.
PFIZER 2015 ANNUAL REVIEW  www.pfizer.com/annual

PATENTS ISSUED TO PFIZER IN 2015

<table>
<thead>
<tr>
<th>In the U.S.</th>
<th>Outside of the U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>129*</td>
<td>1,807*</td>
</tr>
</tbody>
</table>

* Includes Hospira patents. Does not include licensed-in patents.

FOCUSING ON SCIENCE AND PATIENT IMPACT

ONCOLOGY

We’re investigating precision-guided therapies targeting novel signaling and epigenetic pathways, and cancer immunotherapies aimed at modulating the immune system.

I’M WORKING ON...

Puja Sapra
Senior Director, Oncology Research

Jeremy Bartlett
Associate Research Fellow, Drug Product Design
VACCINES

We are tackling some of the most deadly pediatric, adult and adolescent infectious diseases, as well as evaluating therapeutic vaccines across a variety of cancer types.

I'M WORKING ON...

Karin Joos
Senior Director, Biology, Vaccine Immunotherapeutics and Head of Cancer Vaccine Development

Alejandra Gurtman
Program Lead, Staph Aureus Vaccine

WATCH VIDEO

WATCH VIDEO
NEUROSCIENCE & PAIN

We are exploring Parkinson’s, Alzheimer’s and Huntington’s disease, as well as conducting research into trans-diagnostic domains, where we explore how cognition, anxiety and motivation correlate to the manifestation of a neuropsychiatric disorder, and their impact on a patient’s quality of life.

I’M WORKING ON...

Anabella Villalobos
Vice President, Neuroscience and Pain Medicinal Chemistry

David Gray
Senior Director, Parkinson’s Drug Development Team Leader

I’M WORKING ON...

Matt Howe
Postdoctoral Research Fellow, Neuroscience Research Unit

A View into Treating Brain Conditions
CARDIOVASCULAR & METABOLIC

Our clinical-stage pipeline of potential therapies for patients covers a range of metabolic and cardiovascular risk factors, as well as exploring the areas of heart failure and nonalcoholic liver inflammation and damage.

I'M WORKING ON...

Albert Kim
Global Clinical Lead, Cardiovascular and Metabolic Disease

Ann Marie Richard
Principal Scientist, Metabolic Disease

Pfizer’s Legacy and Expertise in Cardiovascular Diseases

WATCH VIDEO
IMMUNOLOGY & INFLAMMATION

We are looking to transform the treatment of chronic inflammatory diseases such as rheumatoid arthritis and gastrointestinal disorders, while investigating potential therapies with application in medical dermatology.

I'M WORKING ON...

Iain Kilty
Senior Director, Rheumatology and Dermatology

WATCH VIDEO

Janet Buhlmann
Senior Principal Scientist, Immunology and Autoimmunity

WATCH VIDEO
RARE DISEASE

Our researchers in rare disease are working to unlock the scientific opportunity of gene therapy for people living with hemophilia, as well as investigating potential therapies for blood and neuromuscular diseases, which are devastating to patients, their families and the larger community.

I'M WORKING ON...

Joseph Nabhan
Principal Scientist, Rare Disease Research Unit

Kena Swanson
Senior Principal Scientist, Vaccine Research and Development

BIOSIMILARS

With our acquisition of Hospira, we are now a leading global biosimilars company with a robust pipeline, best-in-class development capabilities and extensive real-world commercialization experience. We are working hard to extend that leadership by advancing high quality biosimilars to address the evolving needs of patients, payers and health systems.

I'M WORKING ON...

Lisa Skeens
Head of Global Regulatory Affairs, Global Established Pharma
EXPANDING THE R&D ECOSYSTEM

Our strategy looks to foster collaboration across the biomedical ecosystem to deliver innovation to patients. We are working to bring the best science, wherever it resides, into our efforts to find and develop needed therapies.

We attempt to establish flexible collaborations that can have an amplifying and accelerating effect — optimizing shared assets and capabilities and making it possible to pursue more research avenues or de-risking the earlier stage research that may provide the foundation for true medical breakthroughs. In these new forms of collaboration, we are sharing in the risks and rewards and attempting to expedite the pace of innovation and enhance the R&D ecosystem for the benefit of patients.

A HOLISTIC ECOSYSTEM FUELED BY COLLABORATION

BIOTECH / BIG PHARMA
Access to Early and Late Stage Assets and Development Solutions

ACADEMIC PARTNERSHIPS
Innovation through Cutting-Edge Science and Technology

PUBLIC PARTNERSHIPS
Drug Discovery and Translational Medicine Innovation

PATIENT FOUNDATIONS
Joint Funding for Shared Interests

VENTURE CAPITAL / EQUITY INVESTMENT
Funding for Early Stage Products and Technologies